NeoGenomics, Inc. (NEO) – What Are Researchers Thinking About This Stock?

NeoGenomics, Inc. (NASDAQ:NEO) has received a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $18.17.

Several research firms have issued reports on NEO. Benchmark increased their target price on NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Wall Street Zen upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Piper Sandler reiterated an “overweight” rating on shares of NeoGenomics in a research report on Wednesday, October 7th. Finally, Weiss Ratings upgraded NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th.

NeoGenomics Stock Performance

Shares of NEO stock opened at $16.20 on Tuesday. The stock has a market capitalization of $2.08 billion, a P/E ratio of -40.50 and a beta of 1.79. The company has a current ratio of 3.60, a quick ratio of 3.35 and a debt-to-equity ratio of 0.48. The firm’s 50 day moving average is $17.50 and its 200 day moving average is $13.17. NeoGenomics has a 12 month low of $7.07 and a 12 month high of $20.15.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.03 by $0.02. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. The company had revenue of $201.66 million during the quarter, compared to the consensus estimate of $196.93 million. During the same period last year, the firm earned $0.03 EPS. NeoGenomics’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, sell-side analysts anticipate that NeoGenomics will post -0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC increased its position in shares of NeoGenomics by 26.2% during the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after buying an additional 2,549,545 shares during the period. First Trust Advisors LP purchased a new stake in shares of NeoGenomics in the first quarter worth about $45,725,000. American Capital Management Inc. purchased a new stake in shares of NeoGenomics in the second quarter worth about $32,648,000. GW&K Investment Management LLC boosted its position in shares of NeoGenomics by 7.5% in the fourth quarter. GW&K Investment Management LLC now owns 2,238,767 shares of the medical research company’s stock valued at $26,328,000 after acquiring an additional 155,882 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of NeoGenomics by 9.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock valued at $19,842,000 after acquiring an additional 225,588 shares during the period. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology.